News

New analysis reveals Ingrezza's 40 mg dose significantly improves tardive dyskinesia symptoms, showcasing long-term efficacy and safety in patients.

A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain, highlighting the complexity of treatment outcomes.

Explore the psychological impacts of the Israel-Palestine conflict, emphasizing trauma, identity, and the potential for healing and peace through psychiatry.

Explore the critical role of social determinants in mental health, highlighting their impact on wellbeing and the need for interdisciplinary research.

Creative individuals navigate the fine line between solitude and loneliness, discovering how isolation can fuel artistic expression or lead to despair.

Maximillian Fink, MD, a pioneering psychiatrist and advocate for ECT, leaves a lasting legacy in neuropsychiatry and education.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

New research reveals that benzodiazepines and antipsychotics increase mortality risk in hospice patients with Alzheimer disease and dementia.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

AI chatbots prioritize user engagement over mental health, risking harm to vulnerable users. Explore the urgent need for ethical programming and safety measures.

A recent study highlights lumateperone's effectiveness in preventing schizophrenia relapse, showcasing its potential for long-term treatment benefits.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

Explore the evolving significance of Indigenous People's Day and its impact on mental health, community healing, and historical recognition.

"They toil in a sterile field, pack produce on ice fast as death’s freedom allows..."

New research highlights lumateperone's effectiveness as an adjunctive treatment for major depressive disorder, improving depressive symptoms and sexual function.

Take our poll!

Explore the complex neuropsychiatric symptoms of Huntington disease and the challenges in treatment and management for affected patients.

World Mental Health Day emphasizes the importance of mental health access during crises, urging professionals to prioritize their own well-being amidst challenges.

Sleep disruption undermines team coordination in sports, revealing its critical role in collective performance and strategic success.

A recent study reveals higher substance use disorder rates in individuals with ADHD, highlighting significant sex differences and the impact of comorbid psychiatric conditions.